1. Alnylam's Qfitlia™ is FDA-approved, the sixth RNAi drug by the company. 2. Qfitlia™ uniquely lowers antithrombin to enhance blood coagulation, preventing bleeds.
The FDA approval of Qfitlia™ significantly boosts Alnylam's product pipeline, similar to past approvals that drove high market value increases.
The FDA's endorsement strengthens Alnylam's market position and investor confidence, critical for stock valuation.
Immediate market reactions to drug approvals typically influence stock prices quickly, as seen with previous Alnylam therapies post-approval.